177 related articles for article (PubMed ID: 27924072)
1. P53 and Murine Double Mimute 2 (MDM2) Expression Changes and Significance in Different Types of Endometrial Lesions.
Jiang Z; Xu W; Dan G; Liu Y; Xiong J
Med Sci Monit; 2016 Dec; 22():4786-4793. PubMed ID: 27924072
[TBL] [Abstract][Full Text] [Related]
2. Different trends of p53, MDM2 and p14 ARF expression patterns in endometrial adenocarcinomas versus hyperplasia.
Buchynska LG; Nesina IP; Kashuba EV
Exp Oncol; 2007 Dec; 29(4):287-94. PubMed ID: 18199985
[TBL] [Abstract][Full Text] [Related]
3. MDM2 and p53 protein expression in the histologic subtypes of endometrial carcinoma.
Ambros RA; Sheehan CE; Kallakury BV; Ross JS; Malfetano J; Paunovich E; Figge J
Mod Pathol; 1996 Dec; 9(12):1165-9. PubMed ID: 8972476
[TBL] [Abstract][Full Text] [Related]
4. Expression of p53, Ki-67, and CD31 proteins in endometrial polyps of postmenopausal women treated with tamoxifen.
Miranda SP; Traiman P; Cândido EB; Lages EL; Freitas GF; Lamaita RM; Vidigal PV; da Silva Filho AL
Int J Gynecol Cancer; 2010 Dec; 20(9):1525-30. PubMed ID: 21119367
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical expression of p53, MDM2, and p21Waf1 oncoproteins in endometriomas but not adenomyosis.
Goumenou A; Panayiotides I; Mahutte NG; Matalliotakis I; Fragouli Y; Arici A
J Soc Gynecol Investig; 2005 May; 12(4):263-6. PubMed ID: 15866118
[TBL] [Abstract][Full Text] [Related]
6. Transcriptional inactivation of p53, Bax, Bcl-2 and Mdm2 correlates with malignant transformation of the uterine cervix.
Soufla G; Baritaki S; Sifakis S; Zafiropoulos A; Spandidos DA
Int J Biol Markers; 2005; 20(1):18-27. PubMed ID: 15832769
[TBL] [Abstract][Full Text] [Related]
7. Associations of MDM2 SNP309, transcriptional activity, mRNA expression, and survival in stage I non-small-cell lung cancer patients with wild-type p53 tumors.
Chien WP; Wong RH; Cheng YW; Chen CY; Lee H
Ann Surg Oncol; 2010 Apr; 17(4):1194-202. PubMed ID: 19941079
[TBL] [Abstract][Full Text] [Related]
8. Different expression pattern and significance of p14ARF-Mdm2-p53 pathway and Bmi-1 exist between gastric cardia and distal gastric adenocarcinoma.
Yao D; Wang Y; Xue L; Wang H; Zhang J; Zhang X
Hum Pathol; 2013 May; 44(5):844-51. PubMed ID: 23159155
[TBL] [Abstract][Full Text] [Related]
9. Distinctive p53 and mdm2 immunohistochemical expression profiles suggest different pathogenetic pathways in poorly differentiated endometrial carcinoma.
Soslow RA; Shen PU; Chung MH; Isacson C
Int J Gynecol Pathol; 1998 Apr; 17(2):129-34. PubMed ID: 9553809
[TBL] [Abstract][Full Text] [Related]
10. Postmenopausal status, hypertension and obesity as risk factors for malignant transformation in endometrial polyps.
Giordano G; Gnetti L; Merisio C; Melpignano M
Maturitas; 2007 Feb; 56(2):190-7. PubMed ID: 16963204
[TBL] [Abstract][Full Text] [Related]
11. Elevated transcript levels from the MDM2 P1 promoter and low p53 transcript levels are associated with poor prognosis in human pancreatic ductal adenocarcinoma.
Grochola LF; Taubert H; Greither T; Bhanot U; Udelnow A; Würl P
Pancreas; 2011 Mar; 40(2):265-70. PubMed ID: 21404460
[TBL] [Abstract][Full Text] [Related]
12. Expression of fos and jun proto-oncogenes in benign versus malignant human uterine tissue.
Nephew KP; Choi CM; Polek TC; McBride R; Bigsby RM; Khan SA; Husseinzadeh N
Gynecol Oncol; 2000 Mar; 76(3):388-96. PubMed ID: 10684716
[TBL] [Abstract][Full Text] [Related]
13. Discriminating functional and non-functional p53 in human tumours by p53 and MDM2 immunohistochemistry.
Nenutil R; Smardova J; Pavlova S; Hanzelkova Z; Muller P; Fabian P; Hrstka R; Janotova P; Radina M; Lane DP; Coates PJ; Vojtesek B
J Pathol; 2005 Nov; 207(3):251-9. PubMed ID: 16161005
[TBL] [Abstract][Full Text] [Related]
14. [Clinical significance of mdm2 and p53 expression in orbital rhabdomyosarcoma].
Xu XL; Li B; Sun XL; Li LQ
Zhonghua Yan Ke Za Zhi; 2004 Nov; 40(11):755-9. PubMed ID: 15634483
[TBL] [Abstract][Full Text] [Related]
15. Functional interaction between S100A1 and MDM2 may modulate p53 signaling in normal and malignant endometrial cells.
Nakagawa M; Higuchi S; Hashimura M; Oguri Y; Matsumoto T; Yokoi A; Ishibashi Y; Ito T; Saegusa M
BMC Cancer; 2022 Feb; 22(1):184. PubMed ID: 35177036
[TBL] [Abstract][Full Text] [Related]
16. Receptor Activator of Nuclear Factor Kappa B (RANK) and Clinicopathological Variables in Endometrial Cancer: A Study at Protein and Gene Level.
Gómez R; Castro A; Martínez J; Rodríguez-García V; Burgués O; Tarín JJ; Cano A
Int J Mol Sci; 2018 Jun; 19(7):. PubMed ID: 29932437
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of survivin reduces cell proliferation and induces apoptosis in human endometrial cancer.
Ai Z; Yin L; Zhou X; Zhu Y; Zhu D; Yu Y; Feng Y
Cancer; 2006 Aug; 107(4):746-56. PubMed ID: 16826583
[TBL] [Abstract][Full Text] [Related]
18. p53 alteration independently predicts poor outcomes in patients with endometrial cancer: a clinicopathologic study of 131 cases and literature review.
Lee EJ; Kim TJ; Kim DS; Choi CH; Lee JW; Lee JH; Bae DS; Kim BG
Gynecol Oncol; 2010 Mar; 116(3):533-8. PubMed ID: 20006376
[TBL] [Abstract][Full Text] [Related]
19. P53 expression in adenomyosis in endometrial carcinoma patients.
Taskin M; Lallas TA; Shevchuk M; Barber HR
Gynecol Oncol; 1996 Aug; 62(2):241-6. PubMed ID: 8751556
[TBL] [Abstract][Full Text] [Related]
20. P53 regulation of leukemia cells with the blockage of MDM2 by antisense oligonucleotides.
Fang M; Ji X; Tang Y; Liu W
J Huazhong Univ Sci Technolog Med Sci; 2006; 26(4):414-6. PubMed ID: 17120736
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
